Skip to main content

Table 2 Costs

From: Cost and cost-effectiveness of tuberculosis treatment shortening: a model-based analysis

 

South Africa

Brazil

Bangladesh

Tanzania

Reference

a. Guidelines

Healthcare provider costs

 First-line treatment, IP, 1mo (excl drugs)

200 (152–230)

333 (117–479)

17 (12–21)

65 (24–106)

[16, 18, 19]

 First-line treatment, CP, 1mo (excl drugs)

54 (41–62)

333 (117–479)

11 (7–15)

16 (7–24)

[16, 18, 19]

 Drugs, first-line, IP, 1mo

16

7 (6–9)

7 (6–8)

6

[16, 18–20]

 Drugs, first-line, CP, 1mo

19

4 (3–6)

3 (3–3)

2

[16, 18–20]

 Retreatment: all

n/a

n/a

213 (160–266)

430 (310–549)

[16, 18, 19]

 MDR treatment: all

10,215 (8,619–24,580)

5,223 (4,800–5,348)

4,262 (3,836–4,688)

2,507 (2,454–2,561)

[16, 18, 19]

 ART cost in year 1

1,128 (1,117–1,139)

5,875 (5,288–6,463)a

800 (720–880)

315 (283–346)

[21, 22, 49–52]

 ART cost per year (after year 1)

639 (575–703)

600 (540–660)

277 (249–304)

[21, 22, 49–52]

Patient costs

 First-line treatment, IP, 1mo

149 (87–164)

40 (8–131)

314 (283–346)

186 (167–204)

[3, 16, 17]

 First-line treatment, CP, 1mo

117 (34–129)

40 (8–131)

31 (28–34)

44 (40–48)

[3, 16, 17]

 Retreatment: all

n/a

n/a

135 (121–148)

354 (319–390)

[3, 16, 17]

 MDR treatment: all

3,319 (2,987–3,650)

280 (102–1142)

213 (192–234)

454 (409–499)

[3, 16, 17]

 ART cost in year 1

106 (96–117)

23 (4–43)

8 (7–8)

24 (22–26)

[53]

 ART cost per year (after year 1)

85 (77–93)

9 (2–17)

3 (3–3)

10 (9–11)

[53]

 Cost per visit to healthcare facility

8 (7–9)

5 (1–9)

2 (1–2)

5 (4–5)

[3, 16, 17]

b. Current

Healthcare provider costs

 First-line treatment, IP, 1mo (excl drugs)

61 (40–96)

133 (59–285)

17 (12–21)

35 (24–45)

[16, 18, 19]

 First-line treatment, CP, 1mo (excl drugs)

16 (11–26)

133 (59–285)

11 (8–15)

16 (7–24)

[16, 18, 19]

 Drugs, first-line, IP, 1mo

16

7 (6–9)

7 (6–8)

6

[16, 18–20]

 Drugs, first-line, IP, 1mo

19

4 (3–6)

3 (3–3)

2

[16, 18–20]

 Retreatment: all

n/a

n/a

213 (160–266)

429 (310–549)

[16, 18, 19]

 MDR treatment: all

10,215 (8,619–24,580)

5,223 (4,800–5,348)

4,262 (3,836–4,688)

2,507 (2,454–2,561)

[16, 18, 19]

 ART cost in year 1

1,128 (1,117–1,139)

5,875 (5,288–6,463)a

800 (720–880)

315 (283–346)

[21, 22, 49–52]

 ART cost per year (after year 1)

639 (575–703)

600 (540–660)

277 (249–304)

[21, 22, 49–52]

Patient costs

 First-line treatment, IP, 1mo

60 (35–66)

40 (8–131)

314 (283–346)

144 (139–149)

[3, 16, 17]

 First-line treatment, CP, 1mo

27 (8–30)

40 (8–131)

31 (28–34)

41 (37–44)

[3, 16, 17]

 Retreatment: all

n/a

n/a

135 (121–148)

354 (319–390)

[3, 16, 17]

 MDR treatment: all

3,319 (2,987–3,650)

280 (102–1,142)

213 (192–234)

454 (409–499)

[3, 16, 17]

 ART cost in year 1

106 (96–117)

23 (4–43)

8 (7–8)

24 (22–26)

[53]

 ART cost per year (after year 1)

85 (77–94)

9 (2–17)

3 (3–3)

10 (9–11)

[53]

 Cost per visit to healthcare facility

8 (7–9)

5 (1–9)

2 (1–2)

5 (4–5)

[3, 16, 17]

  1. IP intensive phase, CP continuation phase, mo month, excl excluding, ART antiretroviral treatment, MDR multidrug resistant, DST drug resistance testing
  2. aAverage cost per year